Patients who are able to tolerate flexible bronchoscopy
Patients who are deemed unable to safely undergo or tolerate flexible bronchoscopy
were unable to tolerate the prior first-line regimen
There is no upper age limit but the patients must be able to medically tolerate the regimen
Willing to undergo and able to tolerate frequent MRI or CT assessments during the study
Patient is unable to tolerate MRI (foreign body; i.e. pacemaker or other implanted device; claustrophobia; inability to tolerate rectal coil, etc)
Patients who cannot tolerate pneumocystis jirovecii pneumonia (PJP) prophylaxis (i.e., known Bactrim and pentamidine allergies)
Patients must be able to tolerate apheresis procedure, including placement of temporary apheresis line if required
Tolerate a  g ascorbate infusion (screening dose)
Patients that cannot tolerate MRI
Subjects must be able to tolerate apheresis procedure, including placement of temporary apheresis line if required
Patients unable to tolerate transrectal ultrasound.
Subjects must be able to tolerate apheresis procedure, including placement of temporary apheresis line if required
Able to tolerate prone body positioning during radiation therapy
Patients who have had prior everolimus but were not able to tolerate a  mg daily dose
Co-morbidities precluding patient's ability to tolerate BMT
Patients with KPS <  and/or unable to tolerate potentially longer treatment times
Unable to tolerate anti-viral and anti-Pneumocystis jirovecii prophylaxis while on pre-phase and remission induction therapy
Tolerate one test dose ( g) of ascorbate
Patient is able to tolerate apheresis procedure including placement of temporary apheresis catheter if necessary or has prior apheresis product of  x ^ mononuclear (MNC) cells available for use
Patient must be able to tolerate lying in the prone position with arms extended forward
Must be able to tolerate MRI scan with contrast
COHORT II: Patient must be able to tolerate lying in the prone position with arms extended forward
COHORT II: Must be able to tolerate MRI scan with contrast
Able to tolerate pre / post - procedure steroid treatment
Individuals who are not able or willing to tolerate the required prolonged stationary position during treatment (can be up to  hrs of total table time.)
Patients who cannot tolerate intravesical dosing or intravesical surgical manipulation
Patient unable to tolerate lymphodepletion, low-dose IL- and/or IMA product
Tolerate one test dose (g) of ascorbate
Ineligible for curative loco regional treatment and have progressed on or did not tolerate approved treatments of Erivedge (vismodegib, also known as GDC ) and Odomzo (sonidegib, also known as erismodegib or LDE) and have progressed on did not tolerate or are unwilling to try other investigational agents
Willing and able to tolerate brain MRI's with contrast
Patients that cannot tolerate MRI
Subject is not an appropriate candidate for, or unable to tolerate, flexible bronchoscopy procedures
Ability to tolerate intensive therapy with vosaroxin  mg/m^ and standard dose of cytarabine as per investigator discretion
Tolerate a  g ascorbate infusion (screening dose)
Able to tolerate intraperitoneal (IP) port placement and IP treatment administration in the opinion of the enrolling investigator
Patient is unable to tolerate placement of a stereotactic head frame
Patients who cannot tolerate intravesical dosing or intravesical surgical manipulation
Unable to tolerate thromboembolic prophylaxis while on the study
SUB-PROTOCOL AIM A: Previously treated patients who have failed, unable to tolerate, or refused other available active therapies
Tolerate one test dose ( g) of ascorbate
Able to tolerate high-dose cyclophosphamide, fludarabine and high-dose IL-
Able to tolerate high-dose cyclophosphamide, fludarabine, and high-dose IL-
Individuals who are not able or willing to tolerate the required prolonged stationary supine position during treatment (approximately  hrs.)
Patients must be able to tolerate MRI scans
Patients who have previously been unable to tolerate ceritinib, in the opinion of the investigator. Exceptions to this exclusion include nausea, vomiting and diarrhea in patients taking ceritinib under fasted conditions.
Ability to tolerate FCR based therapy
Tolerate one test dose ( g) of ascorbate
Patients that cannot tolerate being scanned for an additional  minutes with arms above their head will be excluded.
Patients with demonstrated allergy to TMZ or who are otherwise unable to tolerate TMZ for any reason will be excluded and replaced if needed; patients who are found after enrollment to be unable to tolerate TMZ will not be a candidate for the vaccine despite being previously enrolled and will be removed from the study and replaced
Patient is able to tolerate being in the MRI scanner for the duration of the study
Individuals who are not able or willing to tolerate the required prolonged stationary position during treatment (can be up to  hours [hrs] of total table time)
Patients that were unable to tolerate at least  cycle of an alkylating agent plus corticosteroid (e.g. melphalan + dexamethasone) or alternative prior regimen because of severe adverse events (e.g. hypersensitivity reaction) may be considered after discussion with the study PI/Medical Monitor.
Patients must have measurable contrast-enhancing progressive or recurrent glioblastoma by MRI within  days of starting treatment; patient must be able to tolerate MRIs
Must be able to tolerate MRI scan procedure
Individuals who are not able or willing to tolerate the required prolonged stationary position during treatment (approximately  hrs.)
Subject is able to tolerate endoscopy
Previously unable to tolerate either supplement due to taste or gastrointestinal (GI) side effects.
Are able to tolerate surgery (i.e., segmentectomy, lobectomy or bilobectomy) as indicated by standard clinical pre-op evaluation, including pulmonary function tests and cardiac evaluation (if indicated)
Able to tolerate high-flow oxygen/air
Able to tolerate enteral drug administration
Ability to tolerate thin liquids by mouth at the time of admission
Able to tolerate prone position and breath hold during CT simulation
Patients must be able to tolerate MRI/CT scans
Patients unable to tolerate discontinued use of anti-coagulants prior to and during the ablation procedure.
Tolerate sitting in a rocking or nonrocking chair
Patients must be able to tolerate digital breast tomosynthesis and full-field digital mammographic imaging required by protocol
EXCLUSION - PATIENT: Unable to tolerate exam (i.e., secondary to untreatable claustrophobia, positioning constraints/unable to lie prone)
Individuals who are not able or willing to tolerate the required prolonged stationary supine position during treatment (approximately  hrs. sonication time)
Subjects who could not tolerate a PI, IMiDs, or a CD-directed cytolytic antibody are eligible to enroll in the study.
Patient is incontinent of urine or stool (which would make them unable to tolerate lying still for  minutes)
Patients unable to tolerate a SPECT/CT mTc-SC scan
Unable to tolerate MRI without anesthesia
Patients able to tolerate PET/MRI scans
Patients who are unable to tolerate surgery
Patient not able to tolerate MRI scan due to claustrophobia or severe pain or allergic reaction to contrast
Unable to tolerate up to  min of PET imaging per imaging session
Deemed unable to safely undergo or tolerate flexible bronchoscopy as per institutional guidelines
Able to tolerate MRI
Patients who cannot tolerate the vaginal ultrasound procedure
Able to tolerate supine position
Able to tolerate an MRI examination
Unable to tolerate  min of PET imaging per imaging session
Patients unable to tolerate a SPECT/CT mTc-MAA and mTc-DTPA scan
Patients who cannot tolerate imaging up to  minutes of total imaging (breaks of several minutes between imaging will be available)
Able to eat a full range of solid food and liquids and tolerate seeds/nuts
Must be able to tolerate PET/CT (i.e. not claustrophobic and able to remain supine)
Patient must be able to tolerate a major surgical procedure based on clinical evaluation, status of their cancer, and any other underlying medical problems
Patients who are able to tolerate flexible bronchoscopy.